Europäische Union - Englisch - EMA (European Medicines Agency)

astrazeneca ab - formoterol fumarate dihydrate, glycopyrronium bromide, budesonide - pulmonary disease, chronic obstructive - drugs for obstructive airway diseases, - trixeo aerosphere is indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (copd) who are not adequately treated by a combination of an inhaled corticosteroid and a long acting beta2 agonist or combination of a long-acting beta2 agonist and a long acting muscarinic antagonist.

Philippinen - Englisch - FDA (Food And Drug Administration)

glaxosmithkline philippines, inc.; distributor: glaxosmithkline philippines, inc. - fluticasone furoate , umeclidinium (as bromide) , vilanterol (as trifenatate) - dry powder for inhalation - 100 mcg/62.5 mcg/25 mcg

Singapur - Englisch - HSA (Health Sciences Authority)

glaxosmithkline pte ltd - fluticasone furoate (micronised); umeclidinium bromide (micronised) eqv to umeclidinium; vilanterol trifenatate (micronised) eqv to vilanterol - powder, metered - fluticasone furoate (micronised) 200 mcg; umeclidinium bromide (micronised) eqv to umeclidinium 62.5 mcg; vilanterol trifenatate (micronised) eqv to vilanterol 25 mcg

Kanada - Englisch - Health Canada

novartis pharmaceuticals canada inc - glycopyrronium (glycopyrronium bromide); indacaterol (indacaterol maleate) - capsule - 50mcg; 110mcg - glycopyrronium (glycopyrronium bromide) 50mcg; indacaterol (indacaterol maleate) 110mcg - antimuscarinics antispasmodics

Europäische Union - Englisch - EMA (European Medicines Agency)

astrazeneca ab - glycopyrronium, formoterol fumarate dihydrate - pulmonary disease, chronic obstructive - formoterol and glycopyrronium bromide - bevespi aerosphere is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (copd).

Kanada - Englisch - Health Canada

novartis pharmaceuticals canada inc - indacaterol (indacaterol acetate); glycopyrronium (glycopyrronium bromide); mometasone furoate - capsule - 150mcg; 50mcg; 160mcg - indacaterol (indacaterol acetate) 150mcg; glycopyrronium (glycopyrronium bromide) 50mcg; mometasone furoate 160mcg - antimuscarinics antispasmodics

Australien - Englisch - Department of Health (Therapeutic Goods Administration)

astrazeneca pty ltd - budesonide, quantity: 160 microgram/actuation; formoterol fumarate dihydrate, quantity: 5 microgram/actuation; glycopyrronium bromide, quantity: 9 microgram/actuation (equivalent: glycopyrronium, qty 7.2 microgram/actuation) - inhalation, pressurised - excipient ingredients: calcium chloride dihydrate; distearoylphosphatidylcholine; norflurane - maintenance treatment to prevent exacerbations and relieve symptoms in adults with moderate, severe, or very severe chronic obstructive pulmonary disease (copd) who require treatment with a combination of an inhaled corticosteroid (ics), a long-acting beta2-agonist (laba), and a long-acting muscarinic antagonist (lama). breztri aerosphere 160/7.2/5 is not indicated for the initiation of therapy in copd.

Europäische Union - Englisch - EMA (European Medicines Agency)

astrazeneca ab - budesonide, formoterol fumarate dihydrate, glycopyrronium bromide - pulmonary disease, chronic obstructive - drugs for obstructive airway diseases, - riltrava aerosphere is indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (copd) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2 agonist or combination of a long-acting beta2 agonist and a long-acting muscarinic antagonist (for effects on symptoms control and prevention of exacerbations see section 5.1).

Australien - Englisch - Department of Health (Therapeutic Goods Administration)

astrazeneca pty ltd - budesonide, quantity: 160 microgram/actuation; formoterol fumarate dihydrate, quantity: 5 microgram/actuation; glycopyrronium bromide, quantity: 9 microgram/actuation (equivalent: glycopyrronium, qty 7.2 microgram/actuation) - inhalation, pressurised - excipient ingredients: calcium chloride dihydrate; distearoylphosphatidylcholine; norflurane - maintenance treatment to prevent exacerbations and relieve symptoms in adults with moderate, severe, or very severe chronic obstructive pulmonary disease (copd) who require treatment with a combination of an inhaled corticosteroid (ics), a long-acting beta2-agonist (laba), and a long-acting muscarinic antagonist (lama). breztri aerosphere 160/7.2/5 is not indicated for the initiation of therapy in copd.

Philippinen - Englisch - FDA (Food And Drug Administration)

glaxosmithkline philippines, inc. - umeclidinium (as bromide) - dry powder for inhalation - 62.5 mcg per actuation (eq. to 55 mcg delivered dose)